Clinical trials: Eye Care
Myopia
A Clinical Evaluation of Two Contact Lenses Used With Three Care Systems
The objective of the study was to compare the clinical performance of the two contact lenses when used in combination with three care systems.
- Trial name
- NCT04195581
- Testing
- comfilcon A, fanfilcon A
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- CooperVision, Inc.
Refractive Errors, Astigmatism
Study of a Hand-held Device Plus Mobile App Versus Standard Eye Care Devices in Measuring Refractive Error of the Eye
Single-center, open-label, prospective study in healthy volunteers desiring refraction for correction of visual acuity to compare a handheld device supported by a mobile application with the phoropter and autorefractor.
- Trial name
- NCT03929588
- Testing
- Hand-held device supported by a mobile application, Phoropter, Autorefractor
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- EyeQue Corp.
Presbyopia
CLEAR CARE® PLUS for Presbyopic Contact Lens Wearers
The purpose of this study is to evaluate CLEAR CARE® PLUS (CCP) compared to non-HYDRAGLYDE® multi-purpose contact lens solutions in presbyopes currently wearing soft contact lenses and experiencing symptoms of dryness.
- Trial name
- NCT02965833
- Testing
- 3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix, Habitual Multi-Purpose Contact Lens Solution, Habitual Contact Lenses
- Volunteers
- 126 people
- Sponsor
- Alcon, a Novartis Company
Contact Lens Wettability
Effect of FID 114675A on Lens Wettability
The purpose of this study is to evaluate lens wettability of contact lenses when used with an investigational multi-purpose disinfecting solution.
- Trial name
- NCT01342107
- Testing
- FID 114675A multi-purpose disinfecting solution (MPDS), Soft contact lens, Blister pack solution
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Alcon Research
Behcet Disease
Phase III Study in Refractory Behcet's Disease
The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study…
- Trial name
- SHIELD (NCT00995709)
- Testing
- AIN457
- Where
- 49 sites in United States, Egypt and 15 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Refractive Error
Clear Care® Plus vs. PeroxiClear™
The purpose of this study is to evaluate Clear Care® Plus compared to PeroxiClear™ for mean residual peroxide in used lens cases collected at Day 30 after neutralization at recommended storage time.
- Trial name
- NCT02413333
- Testing
- Clear Care Plus contact lens solution, PeroxiClear contact lens solution, Silicone hydrogel contact lenses
- Volunteers
- 133 people
- Sponsor
- Alcon Research
Acute Respiratory Failure Requiring Mechanical Ventilation
Eye-Control Trial: Wearable Eye-Tracking Device as Means of Communication
The purpose of this study is to evaluate the feasibility of use of a wearable communication device for critically ill patients who are admitted to the intensive care unit (ICU) and mechanically ventilated.
- Trial name
- NCT04582149
- Testing
- EyeControl Eye-tracking Device
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Emory University
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
RATIONALE: An Opioid Titration Order Sheet that allows healthcare providers to adjust the dose and schedule of pain medication may help improve pain treatment for patients with cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00666211
- Testing
- educational intervention, Titrated pain management, questionnaire administration
- Where
- 11 sites in United States
- Volunteers
- 98 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Medication Adherence, Glaucoma
A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications
Glaucoma is the second leading cause of visual impairment worldwide. Eye drop medications reduce vision loss from glaucoma by at least 60%, but eye drops must be taken every day to be effective.
- Trial name
- NCT03506568
- Testing
- Devers Drop Device (D3) app
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Universal Adherence LLC
Glaucoma
Interactive Study to Increase Glaucoma Adherence to Treatment
Study participants who receive the I-SIGHT intervention will have higher rates of glaucoma treatment compliance (e.g., medication-taking and refill compliance, return for clinical follow-up) and more positive eye health outcomes…
- Trial name
- I-SIGHT (NCT00794170)
- Testing
- Telephone and Print based intervention
- Where
- 2 sites in United States
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Emory University
Uveitis
38 Week Extension Study to CAIN457C2303
A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet's patients with posterior or panuveitis treated with…
- Trial name
- SHIELD (NCT01093846)
- Testing
- AIN457
- Where
- 25 sites in United States, Egypt and 12 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals